Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, First-In-Human, Multicenter, Open-Label Study of TT-00420, Administered Orally in Adult Patients With Advanced Solid Tumors and Triple Negative Breast Cancers

NCT03654547 is registered in ClinicalTrials.gov with TransThera Sciences (Nanjing), Inc. as lead sponsor.

NCT NCT03654547
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03654547 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, First-In-Human, Multicenter, Open-Label Study of TT-00420, Administered Orally in Adult Patients With Advanced Solid Tumors and Triple Negative Breast Cancers
Lead sponsor
TransThera Sciences (Nanjing), Inc.
Phase
Phase 1
Overall status
Completed
Start date
January 8, 2019
Completion date
February 28, 2024
Enrollment
48 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors, triple negative breast cancer